“In the PATHFINDER 2 study, among 32,007 performance-analyzable participants, the multi-cancer early-detection test had a 0.54% cancer detection rate, 60.3% positive predictive value, 99.2% negative predictive value, and 99.64% specificity.”

0.9561 under ledger-default@0.3.0 at snapshot 27745.

What was asked, and where it stands. Provisional until audited.

Review 75% done · 25% counted in review coverage · 50% by the claims' own author only (1 claim, 4 checks)

Share:

Checked in Galedra: score 0.96, strongly supported · not yet reviewed by anyone else “In the PATHFINDER 2 study, among 32,007 performance-analyzable participants, the multi-cancer early-detection test had a 0.54% cancer detection rate, 60.3% positive predictive value, 99.2% negative…” https://galedra.org/investigations/01a0ea99-f5f6-7cc0-ab15-e668bb467db4

“In the PATHFINDER 2 study, among 32,007 performance-analyzable participants, the multi-cancer early-detection test had a 0.54% cancer detection rate, 60.3% positive predictive value, 99.2% negative predictive value, and 99.64% specificity.”

Supported · 0.9561 under ledger-default@0.3.0 at snapshot 27745 · review checks 1 of 4 · provisional until audited.

3 of 4 review checks done · 1 counted · 2 by the author only

See the evidence · Claim card